BRPI1015941A2 - 3-cyanoquinoline tablet formulations and use thereof. - Google Patents
3-cyanoquinoline tablet formulations and use thereof.Info
- Publication number
- BRPI1015941A2 BRPI1015941A2 BRPI1015941A BRPI1015941A BRPI1015941A2 BR PI1015941 A2 BRPI1015941 A2 BR PI1015941A2 BR PI1015941 A BRPI1015941 A BR PI1015941A BR PI1015941 A BRPI1015941 A BR PI1015941A BR PI1015941 A2 BRPI1015941 A2 BR PI1015941A2
- Authority
- BR
- Brazil
- Prior art keywords
- cyanoquinoline
- tablet formulations
- formulations
- tablet
- cyanoquinoline tablet
- Prior art date
Links
- QZZYYBQGTSGDPP-UHFFFAOYSA-N quinoline-3-carbonitrile Chemical compound C1=CC=CC2=CC(C#N)=CN=C21 QZZYYBQGTSGDPP-UHFFFAOYSA-N 0.000 title 1
- 239000007916 tablet composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22253709P | 2009-07-02 | 2009-07-02 | |
| PCT/US2010/040555 WO2011002857A2 (en) | 2009-07-02 | 2010-06-30 | 3-cyanoquinoline tablet formulations and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI1015941A2 true BRPI1015941A2 (en) | 2016-04-19 |
Family
ID=42732381
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1015941A BRPI1015941A2 (en) | 2009-07-02 | 2010-06-30 | 3-cyanoquinoline tablet formulations and use thereof. |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP2448563A2 (en) |
| JP (1) | JP2011012063A (en) |
| KR (1) | KR20120046216A (en) |
| CN (1) | CN102470109A (en) |
| AR (1) | AR077546A1 (en) |
| AU (1) | AU2010266342A1 (en) |
| BR (1) | BRPI1015941A2 (en) |
| CA (1) | CA2766067A1 (en) |
| IL (1) | IL217298A0 (en) |
| MX (1) | MX2012000048A (en) |
| RU (1) | RU2011152105A (en) |
| SG (1) | SG177309A1 (en) |
| TW (1) | TW201113050A (en) |
| WO (1) | WO2011002857A2 (en) |
| ZA (1) | ZA201200366B (en) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101313702B1 (en) | 2005-02-03 | 2013-10-04 | 와이어쓰 | Pharmaceutical composition for treating gefitinib and／or erlotinib resistant cancer |
| EP1942937A1 (en) | 2005-11-04 | 2008-07-16 | Wyeth | Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272 |
| US8022216B2 (en) | 2007-10-17 | 2011-09-20 | Wyeth Llc | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
| BRPI0914790A2 (en) | 2008-06-17 | 2015-10-20 | Wyeth Llc | use of a vinorelbine compound and a hki-272 compound, pharmaceutical composition and neoplasm treatment product and kit |
| US8669273B2 (en) | 2008-08-04 | 2014-03-11 | Wyeth Llc | Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine |
| DK3000467T3 (en) | 2009-04-06 | 2023-03-27 | Wyeth Llc | TREATMENT WITH NERATINIB AGAINST BREAST CANCER |
| CA2780332C (en) | 2009-11-09 | 2018-01-30 | Wyeth Llc | Coated drug spheroids and uses thereof for eliminating or reducing conditions such as emesis and diarrhea |
| AU2010316683B2 (en) * | 2009-11-09 | 2015-10-08 | Wyeth Llc | Tablet formulations of neratinib maleate |
| CN104447541A (en) * | 2013-09-16 | 2015-03-25 | 天津市汉康医药生物技术有限公司 | Bosutinib compound |
| CN105384686B (en) * | 2014-09-04 | 2019-07-26 | 连云港润众制药有限公司 | A kind of bosutinib method for crystallising |
| EP3439639A1 (en) * | 2016-04-08 | 2019-02-13 | Shionogi & Co., Ltd. | Stabilized solid dosage form |
| KR102297116B1 (en) | 2017-03-31 | 2021-09-01 | 닛세이 에이. 에스. 비 기카이 가부시키가이샤 | plastic container |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6297258B1 (en) | 1998-09-29 | 2001-10-02 | American Cyanamid Company | Substituted 3-cyanoquinolines |
| BRPI0307786B8 (en) * | 2002-02-26 | 2021-05-25 | Astrazeneca Ab | pharmaceutical composition, method of preparing the same, methods of inhibiting the rate of precipitation of the agent from solution in the gi tract, and to reduce inter-patient variability with respect to bioavailability and/or plasma concentrations of the agent, and, use of a water-soluble cellulose ether or an ester of a water-soluble cellulose ether |
| CN1835923A (en) | 2003-08-19 | 2006-09-20 | 惠氏控股公司 | Process for preparation of 4-amino-3-quinolinecarbonitriles |
| ATE428421T1 (en) * | 2004-09-17 | 2009-05-15 | Eisai R&D Man Co Ltd | MEDICAL COMPOSITION WITH IMPROVED STABILITY AND REDUCED GELING PROPERTIES |
| AU2006266045A1 (en) * | 2005-07-01 | 2007-01-11 | Wyeth | Crystalline forms of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarb-onitrile and methods of preparing the same |
| WO2008053295A2 (en) * | 2006-10-30 | 2008-05-08 | Wockhardt Research Centre | Pharmaceutical compositions of benzoquinolizine-2-carboxylic acid |
| CN101224185A (en) * | 2007-12-11 | 2008-07-23 | 山东蓝金生物工程有限公司 | Bosutinib sustained release implant for treating solid tumors |
-
2010
- 2010-06-30 CN CN2010800294791A patent/CN102470109A/en active Pending
- 2010-06-30 RU RU2011152105/15A patent/RU2011152105A/en unknown
- 2010-06-30 CA CA2766067A patent/CA2766067A1/en not_active Abandoned
- 2010-06-30 BR BRPI1015941A patent/BRPI1015941A2/en not_active Application Discontinuation
- 2010-06-30 AU AU2010266342A patent/AU2010266342A1/en not_active Abandoned
- 2010-06-30 MX MX2012000048A patent/MX2012000048A/en not_active Application Discontinuation
- 2010-06-30 WO PCT/US2010/040555 patent/WO2011002857A2/en not_active Ceased
- 2010-06-30 SG SG2011094950A patent/SG177309A1/en unknown
- 2010-06-30 EP EP10732568A patent/EP2448563A2/en not_active Withdrawn
- 2010-06-30 KR KR1020127002851A patent/KR20120046216A/en not_active Ceased
- 2010-07-01 JP JP2010151063A patent/JP2011012063A/en not_active Withdrawn
- 2010-07-01 TW TW099121740A patent/TW201113050A/en unknown
- 2010-07-02 AR ARP100102373A patent/AR077546A1/en not_active Application Discontinuation
-
2011
- 2011-12-29 IL IL217298A patent/IL217298A0/en unknown
-
2012
- 2012-01-17 ZA ZA2012/00366A patent/ZA201200366B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2011012063A (en) | 2011-01-20 |
| IL217298A0 (en) | 2012-02-29 |
| CA2766067A1 (en) | 2011-01-06 |
| SG177309A1 (en) | 2012-02-28 |
| MX2012000048A (en) | 2012-01-27 |
| AU2010266342A1 (en) | 2012-01-19 |
| EP2448563A2 (en) | 2012-05-09 |
| WO2011002857A2 (en) | 2011-01-06 |
| RU2011152105A (en) | 2013-08-10 |
| AR077546A1 (en) | 2011-09-07 |
| WO2011002857A3 (en) | 2011-03-10 |
| TW201113050A (en) | 2011-04-16 |
| ZA201200366B (en) | 2012-10-31 |
| CN102470109A (en) | 2012-05-23 |
| KR20120046216A (en) | 2012-05-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR25C1035I1 (en) | NERATINIB MALEATE TABLET FORMULATIONS | |
| LTPA2020003I1 (en) | Bilayer tablet formulations | |
| BRPI1015941A2 (en) | 3-cyanoquinoline tablet formulations and use thereof. | |
| BRPI1008709A2 (en) | compositions and uses thereof. | |
| BR112012013148A2 (en) | pharmaceutical formulation and use | |
| BR112012005736A2 (en) | substituted dihydro benzocycloalkyloxymethyl oxazolapyrimidinones, preparation and use thereof | |
| BRPI1014160A2 (en) | Nanoparticle Formulations and Applications | |
| BR112012011733A2 (en) | immediate release tablet formulations | |
| BRPI0911656A2 (en) | nanoparticle formulations and uses thereof | |
| BR112012003792A2 (en) | topical gel and use of topical gel. | |
| SMT201400069B (en) | Pharmaceutical formulation | |
| BRPI1016117A2 (en) | isoxazole-isoxazole and isoxasol-isothiazole derivatives. | |
| IT1403847B1 (en) | PHARMACEUTICAL COMPOSITIONS INCLUDING RIFAXIMINA AND THEIR USE. | |
| BR112012004335A2 (en) | compound, pharmaceutical composition, and use of the compound. | |
| EP2647381A4 (en) | TABLET WITH ORAL DISINTEGRATION | |
| GT201200303A (en) | PHARMACEUTICAL FORMULATIONS | |
| BR112012003844A2 (en) | pttv vaccines and diagnosis | |
| BR112012003800A2 (en) | composition, peptide, and pharmaceutical formulation. | |
| BRPI1014898A2 (en) | hair cosmetic. | |
| BRPI1014388A2 (en) | solid preparation. | |
| BRPI1011036A2 (en) | use | |
| BRPI0915527A2 (en) | pepitides, pharmaceutical composition and exosomes comprising the same, methods and uses | |
| BRPI0908455A2 (en) | flibanserin formulations | |
| EP2612657A4 (en) | TABLET WITH ORAL DISINTEGRATION | |
| BR112012002311A2 (en) | compound, pharmaceutical composition, and use of the compound. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |